0000000000294904

AUTHOR

Caroline Laborde

showing 3 related works from this author

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

2020

Platelet aggregation inhibitors (PAI) have widely proven their efficiency for the prevention of ischemic cardiovascular events. We aimed to describe PAI prescription in an elderly multimorbid population and to determine the factors that influence their prescription, including the impact of age, comorbidities and frailty, evaluated through a comprehensive geriatric assessment. This cross-sectional study included all patients admitted to the acute geriatric department of a university hospital from November 2016 to January 2017. We included 304 consecutive hospitalized patients aged 88.7 &plusmn

medicine.medical_specialtymultimorbidityHealth Toxicology and MutagenesisFrail ElderlyPopulationlcsh:MedicineunderuseDiseasefrailty030204 cardiovascular system & hematologyoveruseelderlyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMedical history030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'educationplatelet aggregation inhibitorsGeriatric AssessmentAgedAged 80 and overeducation.field_of_studyMini–Mental State Examinationmedicine.diagnostic_test[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologylcsh:RPublic Health Environmental and Occupational HealthOdds ratiocomprehensive geriatric assessmentConfidence intervalCross-Sectional StudiesagePlatelet aggregation inhibitorFemaleantiplatelet agentsbusinessInternational Journal of Environmental Research and Public Health
researchProduct

Évaluation de la prescription des inhibiteurs de la pompe à protons chez la personne âgée de 75 ans et plus dans un service de gériatrie aiguë

2017

Resume Introduction et objectifs Les inhibiteurs de la pompe a protons (IPP) sont tres prescrits en France et seraient responsables d’effets indesirables non negligeables surtout chez la personne âgee (PA). Afin de limiter leur mesusage et un surcout pour la securite sociale, la Haute Autorite de sante (HAS) a edite des recommandations de prescription strictes. Nous avons conduit une etude chez la PA dont l’objectif principal etait d’evaluer le taux de prescription d’IPP hors recommandations de la HAS. Methode Il s’agissait d’une etude prospective, monocentrique et observationnelle portant sur des PA de 75 ans et plus admises dans un service de geriatrie aigue, sur une periode de 6 mois. La…

03 medical and health sciences0302 clinical medicinePharmacology (medical)030212 general & internal medicine030226 pharmacology & pharmacy3. Good healthTherapies
researchProduct